chufangao/CTO huggingface dataset:
Clinical trial NCT04346888: A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamic and Pharmacokinetic of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-07-23
Primary completion date: 2021-08-24
Completion date: 2021-08-24
Clinical trial NCT03784963: Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD
Official title: Open-Label Prospective Randomized Control Trial to Investigate the Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Device
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Low enrollment
Enrollment: 35.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-01-23
Primary completion date: 2020-07-15
Completion date: 2020-07-15
Baseline population: Study terminated by PI for low/no enrollment prior to primary and secondary endpoints. All efforts were taken to gather all possible data.
Limitations and caveats: Study terminated by PI for low/no enrollment prior to primary and secondary endpoints. All efforts were taken to gather all possible data.
Plan to share individual participant data: NO
Clinical trial NCT03055767: Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population
Official title: Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Randomized Double Blinded Placebo Cross-over Study in the Pediatric Pain Population
Sponsor: University of California, Irvine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-01
Primary completion date: 2018-11-30
Completion date: 2020-04-20
Baseline population: 15 subjects randomized into the baseline, double-blind period (cross-over).
Limitations and caveats: A lack of diversity in subject demographics and age. Didn't control for patients seeking alternative therapies during the study period, nor attempt to control concomitant medications.~Patients with comorbidities can have an impact on the treatment effect. PedMIDAS may not account for seasonal changes or patients with modified school schedules.~Continuation of baseline therapy is a confounding variable. Pain diary records required follow-up. Data collection relied in part on subject recall.
Plan to share individual participant data: NO
Clinical trial NCT03518112: Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
Official title: Phase II Study of the Combination of Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to Competing Studies
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-18
Primary completion date: 2021-05-27
Completion date: 2021-05-27
Clinical trial NCT03265717: DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia
Official title: A Phase II Study of INVAC-1 as Treatment of Patients With High-risk Chronic Lymphocytic Leukemia
Sponsor: Invectys (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: sponsor decision
Enrollment: 26.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-25
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03905109: Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
Official title: Phase 2b/3, Randomized, Double Blind, Placebo Controlled Induction Phase Followed by a Maintenance Phase to Evaluate the Efficacy & Safety of ABX464 in Patients With Moderate to Severe Active Crohn's Disease & to Determine the Optimal Dose
Sponsor: Abivax S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Study design revised and to be found under new NCT06456593 ABX464-202
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-09-19
Primary completion date: 2022-09-19
Completion date: 2022-09-19
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05070104: CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Official title: Phase I Study of the First-In-Class Agent CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Sponsor: Cornerstone Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: no funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-03-30
Primary completion date: 2024-03-01
Completion date: 2024-11-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05452174: Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)
Official title: Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)
Acronym: ESNAP
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: transfer of PI to new organization
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-06-13
Primary completion date: 2023-10-29
Completion date: 2023-10-29
Plan to share individual participant data: NO
Clinical trial NCT04860258: COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities
Official title: COVID-19: A Phase 3 Multicenter Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Above With Co-morbidities
Sponsor: CureVac (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The Principal Investigators and CureVac decided to terminate the trial early following a change to the risk/benefit profile.
Enrollment: 129.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-22
Primary completion date: 2021-09-21
Completion date: 2021-09-21
Baseline population: The Safety Analysis Set (SAS) consisted of all participants who received at least 1 dose of CVnCoV and for whom any post-vaccination safety data were available.
Limitations and caveats: Participant recruitment was smaller than planned due to early recruitment halt. The Principal Investigators and CureVac decided to terminate the trial early following a change to the risk/benefit profile.
Clinical trial NCT05356403: CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects With Moderate-to-Severe Pruritus With an up to 52-Week Long-term Extension
Sponsor: Cara Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Corporate decision to discontinue work in advanced chronic kidney disease
Enrollment: 105.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-26
Primary completion date: 2024-02-26
Completion date: 2024-02-26
Plan to share individual participant data: NO
Clinical trial NCT04511650: Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
Official title: Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
Acronym: RESCUE
Sponsor: EyePoint Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: After completion of Step 1 Part 1, the Sponsor discontinued the study based on challenges associated with recruiting and monitoring patients in the current pandemic environment.
Enrollment: 31.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-10-21
Primary completion date: 2021-02-26
Completion date: 2021-02-26
Plan to share individual participant data: NO
Clinical trial NCT03861767: REMAP Trial for Optimizing Surgical Outcomes at UPMC
Official title: Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Optimizing Surgical Outcomes at UPMC
Acronym: UPMCREMAP
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Not enough enrollment due to the COVID19 pandemic.
Enrollment: 302.0 (ACTUAL)
Number of arms: 10.0
Start date: 2019-04-15
Primary completion date: 2022-09-23
Completion date: 2022-09-23
Baseline population: None of the participants were randomized to the high-dose long course combination of drug dose and preoperative duration.
Limitations and caveats: Recruitment was terminated early and was limited by the COVID-19 pandemic, as such the study is underpowered and could not meet its set goals. No patients fell in the high dose long course group since no participants were randomized to that group
Plan to share individual participant data: YES
IPD sharing description: De-identified participant-level data underlying the results reported in journal articles, subject to appropriate security controls, may be available for sharing with other researchers.
IPD time frame: Relevant data may be available 1 year following publication
IPD access criteria: Data access is subject to a methodologically sound proposal and the necessary data sharing agreements.
Clinical trial NCT03601507: Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
Official title: Biomarker Modulation by Alpelisib (BYL719) in Transorally Resectable, HPV-Associated HNSCC: A Phase II Window Trial
Sponsor: University of Arizona (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Novartis has chosen to withdraw support for this trial
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-11
Primary completion date: 2022-05-24
Completion date: 2022-05-24
Limitations and caveats: This study stopped accrual early as the investigational product (IP) manufacturer, Novartis, terminated the study stopping provision of IP. 6 out of 20 subjects were accrued, 5 of which completed study. Due to early termination with few patients, only the counts of events have been calculated and no testing was done.
Plan to share individual participant data: NO
Clinical trial NCT02951117: A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
Official title: A Phase 1b, Open Label, Multicenter, Dose Escalation Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-31
Primary completion date: 2020-07-28
Completion date: 2021-04-28
Clinical trial NCT03023904: Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
Official title: Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
Sponsor: Vanderbilt-Ingram Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Research cancelled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-12-29
Primary completion date: 2019-07-30
Completion date: 2020-07-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04582344: Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)
Official title: Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Sponsor: Health Institutes of Turkey (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 10214.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-14
Primary completion date: 2022-06-30
Completion date: 2022-07-27
Plan to share individual participant data: NO
Clinical trial NCT04467515: A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
Official title: A Multi-Center Open Label Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and GEJ Cancer
Sponsor: Precirix (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Per Strategic Sponsor decision
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-14
Primary completion date: 2023-12-11
Completion date: 2023-12-11
Clinical trial NCT03254394: Lidocaine for Oxaliplatin-induced Neuropathy
Official title: Intravenous Lidocaine for Preventing Painful Oxaliplatin-induced Peripheral Neuropathy (OIPN)
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 26.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-15
Primary completion date: 2020-09-28
Completion date: 2021-04-01
Baseline population: This includes only patients who are enrolled and randomized into 2 groups.
Limitations and caveats: Due to the COVID-19 pandemic, the study finished earlier than planned. The total number of patients enrolled was 26 instead of 30.
Plan to share individual participant data: YES
IPD sharing description: IPD will be shared 6 months after publication of the results in a peer-reviewed journal, upon submission of a robust data analysis plan to the study investigators.
IPD time frame: 6 months after publication
IPD access criteria: IPD will be shared 6 months after publication of the results in a peer-reviewed journal, upon submission of a robust data analysis plan to the study investigators.
Clinical trial NCT04162366: A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
Official title: Multi-center, Blinded, Randomized Study With Aprocitentan in Subjects With Uncontrolled Blood Pressure and Chronic Kidney Disease Stage 3 or 4.
Acronym: INSPIRE-CKD
Sponsor: Idorsia Pharmaceuticals Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: A business decision was made to not initiate this study
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-01-31
Primary completion date: 2021-06-30
Completion date: 2021-07-15
Plan to share individual participant data: NO
Clinical trial NCT05218408: CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
Official title: A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type Glioblastoma
Acronym: CYNK001GBM02
Sponsor: Celularity Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: No enrolled subjects
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-08
Primary completion date: 2024-02-29
Completion date: 2024-05-31
Clinical trial NCT03395353: A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder
Official title: A Long-term Safety Study of Duloxetine Hydrochloride in the Treatment of Japanese Children and Adolescents With Depressive Disorder
Sponsor: Shionogi Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 151.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-01-29
Primary completion date: 2020-07-04
Completion date: 2020-07-04
Baseline population: All enrolled participants who received at least one dose of study drug. One participant received no dose of study drug and was not included in the analysis.
Plan to share individual participant data: NO
Clinical trial NCT03505099: Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2
Official title: A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Acronym: SPR1NT
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-02
Primary completion date: 2021-06-15
Completion date: 2021-06-15
Limitations and caveats: Link to the full study results: https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17902
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.
Clinical trial NCT02460484: Safety of Autologous Human Umbilical Cord Blood Treatment for Perinatal Arterial Ischemic Stroke
Official title: Safety of Autologous Human Umbilical Cord Blood Treatment for Perinatal
Sponsor: AdventHealth (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: Restructuring Cell Lab
Enrollment: 10.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2015-04-30
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02454205: An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
Official title: Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial
Acronym: NEXT
Sponsor: University of Cape Town (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 154.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-11-12
Primary completion date: 2020-12-31
Completion date: 2021-08-30
Plan to share individual participant data: NO
Clinical trial NCT03635112: Efficacy and Safety of TD-1473 in Crohn's Disease
Official title: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo˗Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy With 2 Doses of TD-1473 in Subjects With Moderately-to-Severely Active Crohn's Disease
Acronym: DIONE
Sponsor: Theravance Biopharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated by the sponsor on 16 November 2021 after a planned review by the Independent Data Monitoring Committee.
Enrollment: 167.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-19
Primary completion date: 2021-12-30
Completion date: 2021-12-30
Baseline population: Intent-to-Treat Analysis Set: Comprised all randomized participants who received at least one dose of study drug.
Limitations and caveats: The study was terminated by the sponsor on 16 November 2021 after a planned review by the Independent Data Monitoring Committee.
Plan to share individual participant data: NO
IPD sharing description: Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.
Clinical trial NCT06026358: Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands
Official title: Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands. An Internally Placebo Controlled, Partly Blinded Clinical Pilot Study
Sponsor: Medical University of Graz (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: lack of ressources
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-10-31
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT05104905: A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
Official title: A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma (Macrophage Antibody To Inhibit Immune Suppression in RENAl Cell and COLon Carcinomas)
Acronym: RENACOL
Sponsor: Faron Pharmaceuticals Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Since no patients have been enrolled in RENACOL, and safety and tolerability data is rapidly accumulating in another ongoing study, sponsor considered that RENACOL study is no longer needed to assess the safety profile of bexmarilimab
Enrollment: 0.0 (ACTUAL)
Number of arms: 8.0
Start date: 2021-10-07
Primary completion date: 2022-01-28
Completion date: 2022-01-28
Clinical trial NCT03710564: Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
Official title: A Multicenter, Randomized, Double-masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6 mg q4 Weeks Compared to Aflibercept 2 mg q4 Weeks in Patients With Neovascular Age-related Macular Degeneration (nAMD) With Persistent Retinal Fluid (MERLIN)
Acronym: MERLIN
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 535.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-30
Primary completion date: 2020-12-21
Completion date: 2021-07-01
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT05304663: Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
Official title: A Study to Evaluate the Safety and Efficacy of Different Administration Sequences of L19TNF in Combination With Lomustine in Patients With Glioblastoma at First Progression
Acronym: GLIOASTRA
Sponsor: Philogen S.p.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: The Sponsor had no further plan for the study in object
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-01
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO